Emerging medical treatments for hidradenitis suppurativa - 23/07/20
Abstract |
Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting intertriginous skin areas, and it is characterized by recurrent painful episodes of inflammatory drainage. Although the pathophysiology of HS is not fully understood, recent research points to an imbalance of cytokines as a contributing factor to the associated symptoms of purulent drainage and sinus tract formation. HS lesions are often characterized by a superimposed pathogenic/commensal bacterial infection that can improve with targeted antibiotic therapy. New medical treatments have emerged in recent years, many of which specifically work against a variety of proinflammatory mediators associated with HS. These newer, specified treatment options, in conjunction with surgery and lasers, are thought to provide positive outcomes and an overall improvement in quality of life in patients with HS.
Le texte complet de cet article est disponible en PDF.Key words : hidradenitis suppurativa, inflammatory disorders, medical therapies, treatment
Abbreviations used : HS, IL, JAK, PDT, PG, STAT, TNF
Plan
Funding sources: None. |
|
Disclosure: Author Lyons is an investigator for Lenicura and General Electric. Dr Nicholson is an unpaid committee member of the Hidradenitis Suppurativa Foundation. Dr Hamzavi has been an investigator for Lenicura and General Electric, is a consultant for Incyte, is on the AbbVie advisory board (noncompensated), and is the current president of the Hidradenitis Suppurativa Foundation (noncompensated). Drs Shabeeb and Braunberger and Author Peacock have no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 83 - N° 2
P. 554-562 - août 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?